APP and Alzheimer disease: Furthermore, it has been suggested that CR3 may be a potential therapeutic target for the treatment of AD, as knocking out of CR3 has been shown to decrease Aβ deposits in the brain of APP‐transgenic mice and increase extracellular Aβ degradation by microglia (Czirr et al, 2017).